Existing preclinical studies have shown that the multi-kinase inhibitor nintedanib, which targets growth factors like vascular endothelial growth factor, has shown promise in preventing radiation pneumonitis (RP) and reducing the incidence of pulmonary fibrosis [35]. Here, VEGFA is linked to radiation pneumonitis.